Phase I trial of ICP-332
Latest Information Update: 28 Mar 2022
At a glance
- Drugs ICP-332 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- 22 Mar 2022 Results presented in the InnoCare financial media release.
- 22 Mar 2022 Status changed from recruiting to completed, according to the InnoCare media release.
- 15 Aug 2021 According to InnoCare media release, first subject has been dosed in this study